PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• PDS Biotechnology (PDSB) is set to announce its Q2 2025 earnings results on August 12th, with analysts expecting a loss of ($0.24) per share.
• The company's stock recently traded at $1.14 and has experienced a market capitalization of $52.02 million along with a negative price-to-earnings ratio of -1.20.
• HC Wainwright has maintained a "buy" rating on PDS Biotechnology with a price target of $13.00, while Wall Street Zen downgraded the stock from a "hold" to a "sell" rating.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Stock Performance

NASDAQ:PDSB traded down $0.01 during mid-day trading on Friday, hitting $1.11. 248,191 shares of the stock were exchanged, compared to its average volume of 420,059. The stock has a market capitalization of $50.74 million, a price-to-earnings ratio of -1.18 and a beta of 0.95. The firm's 50-day simple moving average is $1.36 and its 200 day simple moving average is $1.33. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.33 and a current ratio of 2.33. PDS Biotechnology has a fifty-two week low of $0.85 and a fifty-two week high of $4.29.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price objective on shares of PDS Biotechnology in a report on Tuesday, July 1st. Wall Street Zen cut PDS Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, June 14th.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.